Concepedia

M. Phillip DeYoung

MP

12

Publications

2.1K

Citations

12

H-Index

2006

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Harvard University

Massachusetts General Hospital

Massachusetts Eye and Ear Infirmary

Hospital Universitario Ramón y Cajal

M. Phillip DeYoung is an author at GlaxoSmithKline (United States) specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

2006–2023

12

Publications

12

Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling

M. Phillip DeYoung, Peter Horak, Avi Sofer et al. · Genes & Development · 2008 · 688 citations · Full text

p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis

James W. Rocco, Chee‐Onn Leong, Nicolas Kuperwasser et al. · Cancer Cell · 2006 · 421 citations · Full text

, , +11

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

Chee‐Onn Leong, N. Vidnovic, M. Phillip DeYoung et al. · Journal of Clinical Investigation · 2007 · 267 citations · Full text

Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis

Peter Horak, Andrew Crawford, Douangsone D. Vadysirisack et al. · Proceedings of the National Academy of Sciences · 2010 · 200 citations · Full text

, , +15

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Joaquı́n Mateo, Gopinath Ganji, Charlotte Lemech et al. · Clinical Cancer Research · 2017 · 138 citations · Full text

Rows per page

1–5 of 12